Xiaonan Hong

4.8k total citations
71 papers, 1.7k citations indexed

About

Xiaonan Hong is a scholar working on Pathology and Forensic Medicine, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Xiaonan Hong has authored 71 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 50 papers in Pathology and Forensic Medicine, 43 papers in Oncology and 18 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Xiaonan Hong's work include Lymphoma Diagnosis and Treatment (50 papers), Viral-associated cancers and disorders (22 papers) and CNS Lymphoma Diagnosis and Treatment (10 papers). Xiaonan Hong is often cited by papers focused on Lymphoma Diagnosis and Treatment (50 papers), Viral-associated cancers and disorders (22 papers) and CNS Lymphoma Diagnosis and Treatment (10 papers). Xiaonan Hong collaborates with scholars based in China, United States and Japan. Xiaonan Hong's co-authors include Ye Guo, Biyun Wang, Junning Cao, Xuejun Ma, Jie Jin, Evgenii A. Osmanov, Helgi van de Velde, Hongfen Lu, Jun Zhu and Ting Liu and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Xiaonan Hong

70 papers receiving 1.7k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Xiaonan Hong China 20 1.0k 930 416 309 248 71 1.7k
Hye Jin Kang South Korea 26 822 0.8× 905 1.0× 461 1.1× 254 0.8× 235 0.9× 120 1.8k
Enrico Derenzini Italy 25 766 0.7× 1.2k 1.3× 275 0.7× 344 1.1× 405 1.6× 99 1.9k
Stefan Dirnhofer Switzerland 22 539 0.5× 548 0.6× 377 0.9× 324 1.0× 367 1.5× 89 1.6k
C. Portlock United States 21 732 0.7× 1.1k 1.2× 367 0.9× 438 1.4× 160 0.6× 36 1.6k
Eliza A. Hawkes Australia 20 847 0.8× 1.0k 1.1× 230 0.6× 382 1.2× 198 0.8× 133 1.6k
Lisa H. Morrissey United States 14 859 0.8× 768 0.8× 268 0.6× 372 1.2× 132 0.5× 27 1.4k
Graham W. Slack Canada 24 1.1k 1.1× 1.7k 1.8× 278 0.7× 660 2.1× 224 0.9× 97 2.2k
Liliana Devizzi Italy 22 960 0.9× 1.5k 1.6× 376 0.9× 478 1.5× 124 0.5× 59 1.9k
Patricia Marinello United States 21 1.5k 1.4× 704 0.8× 314 0.8× 153 0.5× 345 1.4× 90 1.9k
Ilske Oschlies Germany 26 916 0.9× 1.7k 1.8× 262 0.6× 383 1.2× 212 0.9× 87 2.1k

Countries citing papers authored by Xiaonan Hong

Since Specialization
Citations

This map shows the geographic impact of Xiaonan Hong's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xiaonan Hong with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xiaonan Hong more than expected).

Fields of papers citing papers by Xiaonan Hong

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Xiaonan Hong. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xiaonan Hong. The network helps show where Xiaonan Hong may publish in the future.

Co-authorship network of co-authors of Xiaonan Hong

This figure shows the co-authorship network connecting the top 25 collaborators of Xiaonan Hong. A scholar is included among the top collaborators of Xiaonan Hong based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Xiaonan Hong. Xiaonan Hong is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Chen, Guangliang, Qunling Zhang, Ran Li, et al.. (2024). Chidamide plus R‐GDP for relapsed/refractory diffuse large B‐cell lymphoma in patients ineligible for autologous transplantation: A prospective, single‐arm, phase II study. Cancer Medicine. 13(16). e70142–e70142. 3 indexed citations
2.
Townsend, William, Wolfgang Hiddemann, Christian Buske, et al.. (2023). Obinutuzumab Versus Rituximab Immunochemotherapy in Previously Untreated iNHL: Final Results From the GALLIUM Study. HemaSphere. 7(7). e919–e919. 27 indexed citations
3.
Ji, Dongmei, Zuguang Xia, Kai Xue, et al.. (2022). Four cycles of R-CHOP followed by two applications of rituximab based on negative interim PET/CT: an analysis of a prospective trial. BMC Cancer. 22(1). 403–403. 2 indexed citations
4.
Kostakoglu, Lale, Maurizio Martelli, Laurie H. Sehn, et al.. (2021). End-of-treatment PET/CT predicts PFS and OS in DLBCL after first-line treatment: results from GOYA. Blood Advances. 5(5). 1283–1290. 36 indexed citations
5.
Chi, Yihebali, Zhiwei Fang, Xiaonan Hong, et al.. (2018). Safety and Efficacy of Anlotinib, a Multikinase Angiogenesis Inhibitor, in Patients with Refractory Metastatic Soft-Tissue Sarcoma. Clinical Cancer Research. 24(21). 5233–5238. 245 indexed citations
6.
Liu, Xin, Huijie Wang, Xianghua Wu, Xiaonan Hong, & Zhiguo Luo. (2017). Phase II study of doxorubicin and thalidomide in patients with refractory aggressive fibromatosis. Investigational New Drugs. 36(1). 114–120. 5 indexed citations
7.
Kostakoglu, Lale, Maurizio Martelli, Laurie H. Sehn, et al.. (2017). Baseline PET-Derived Metabolic Tumor Volume Metrics Predict Progression-Free and Overall Survival in DLBCL after First-Line Treatment: Results from the Phase 3 GOYA Study. Blood. 130(Suppl_1). 824–824. 20 indexed citations
8.
Chi, Yihebali, Yongkun Sun, Jianqiang Cai, et al.. (2016). Phase II study of anlotinib for treatment of advanced soft tissues sarcomas.. Journal of Clinical Oncology. 34(15_suppl). 11005–11005. 21 indexed citations
9.
Robak, Tadeusz, Huiqiang Huang, Jie Jin, et al.. (2015). Bortezomib-Based Therapy for Newly Diagnosed Mantle-Cell Lymphoma. New England Journal of Medicine. 372(10). 944–953. 261 indexed citations
10.
Luo, Zhiguo, Xiaowei Zhang, Peng Wei, et al.. (2015). A Phase II Study of Gemcitabine, Vincristine, and Cisplatin (Gvp) As Second-Line Treatment for Patients with Advanced Soft Tissue Sarcoma. Medicine. 94(43). e1777–e1777. 4 indexed citations
11.
Cao, Bing, Xiaoyan Zhou, Dongmei Ji, et al.. (2012). Central nervous system involvement in adult patients with diffuse large B-cell lymphoma: Influence of rituximab. Oncology Letters. 4(3). 541–545. 3 indexed citations
12.
Coiffier, Bertrand, Evgenii A. Osmanov, Xiaonan Hong, et al.. (2011). Bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 trial. The Lancet Oncology. 12(8). 773–784. 81 indexed citations
13.
14.
Guo, Ye, Yun Fan, Kangsheng Gu, et al.. (2011). Oral fludarabine in combination with doxorubicin and dexamethasone as first-line therapy for nodal peripheral T-cell lymphomas: early results of a prospective multicenter study. Cancer Chemotherapy and Pharmacology. 69(2). 387–395. 1 indexed citations
15.
Hong, Xiaonan, et al.. (2010). Clinical features and treatment outcomes of 14 cases of primary ovarian non-Hodgkin’s lymphoma: a single-center experience. Medical Oncology. 28(4). 1559–1564. 14 indexed citations
16.
Wang, Biyun, et al.. (2008). Immunohistochemical expression and clinical significance of P‐glycoprotein in previously untreated extranodal NK/T‐cell lymphoma, nasal type. American Journal of Hematology. 83(10). 795–799. 83 indexed citations
17.
Wang, Zhonghua, Binghe Xu, Dongxin Lin, et al.. (2008). XRCC1 polymorphisms and severe toxicity in lung cancer patients treated with cisplatin-based chemotherapy in Chinese population. Lung Cancer. 62(1). 99–104. 47 indexed citations
18.
Wang, Jialei, Jin Li, Xiaonan Hong, et al.. (2007). Retrospective case series of gemcitabine plus cisplatin in the treatment of recurrent and metastatic nasopharyngeal carcinoma. Oral Oncology. 44(5). 464–470. 29 indexed citations
19.
Guo, Ye, Jiade J. Lu, Xuejun Ma, et al.. (2007). Combined chemoradiation for the management of nasal natural killer (NK)/T-cell lymphoma: Elucidating the significance of systemic chemotherapy. Oral Oncology. 44(1). 23–30. 27 indexed citations
20.
Hong, Xiaonan. (2006). Clinical characteristic and current status of treatment for nasal NK/T cell lymphoma. Zhongguo aizheng zazhi. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Hye Jin Kang Breakdown of academic impact, for papers by Enrico Derenzini Breakdown of academic impact, for papers by Stefan Dirnhofer Breakdown of academic impact, for papers by C. Portlock Breakdown of academic impact, for papers by Eliza A. Hawkes Breakdown of academic impact, for papers by Lisa H. Morrissey Breakdown of academic impact, for papers by Graham W. Slack Breakdown of academic impact, for papers by Liliana Devizzi Breakdown of academic impact, for papers by Patricia Marinello Breakdown of academic impact, for papers by Ilske Oschlies
Rankless by CCL
2026